A trusted and essential partner
to the biopharmaceutical
industry, providing 27 years
of in-depth research, analysis
and data on innovation
and excellence —
from biology to the patient.

Get a Free Trial

4:49 PM Aug 16, 2019
BioCentury  |  Product Development

China’s biosimilars in fast lane

Though coming from behind, China is cracking the seal on its biosimilar market and may even be poised to over-take the U.S. and Europe in less than a decade.

Read More
3:16 PM Aug 16, 2019
BioCentury  |  Finance

Chinese investment in U.S. biotechs to slow further

Chinese VCs say the slowing of investments into U.S. biotechs is likely to get worse before it gets better. In addition to continued CFIUS concerns and the ongoing trade war, capital inflows to...

Read More
1:40 PM Aug 16, 2019
BioCentury  |  Product Development

ACRES’ plan to harmonize clinical trials across many lands

With the launch of its clinical site accreditation program, ACRES has taken the first step toward its larger goal of creating a clinical research infrastructure that is digitally connected and...

Read More
6:44 PM Aug 15, 2019
BC Innovations  |  Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of...

Read More
4:07 PM Aug 15, 2019
BC Innovations  |  Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

Adaptive’s float to more than $5 billion after its June IPO is largely based on its ambition to compete with the likes of Grail and Guardant in early diagnosis of cancer and other diseases by...

Read More
1
2
3
4
5

Browse

{{ item.title }}
Browse all categories